Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
Saved in:
| Title: | Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. |
|---|---|
| Authors: | Harbeck, N.1 (AUTHOR) nadia.harbeck@med.uni-muenchen.de, Modi, S.2 (AUTHOR), Pusztai, L.3 (AUTHOR), Ohno, S.4 (AUTHOR), Wu, J.5 (AUTHOR), Kim, S.-B.6 (AUTHOR), Yoshida, A.7 (AUTHOR), Fabi, A.8 (AUTHOR), Cao, X.9,10 (AUTHOR), Joseph, R.11 (AUTHOR), Li, R.12 (AUTHOR), Żurawski, B.13 (AUTHOR), Escrivá-de-Romaní, S.14,15 (AUTHOR), Meneguetti, R.16 (AUTHOR), Supavavej, A.17 (AUTHOR), Chen, S.-C.18 (AUTHOR), Liu, Z.19 (AUTHOR), Kelly, C.20,21 (AUTHOR), Curigliano, G.22,23 (AUTHOR), Symmans, W.F.24 (AUTHOR) |
| Source: | Annals of Oncology. Feb2026, Vol. 37 Issue 2, p166-179. 14p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.10.019 |
